Hypoglycemic, antilipidemic and antioxidant effects of valproic acid in alloxan-induced diabetic rats

This study was designed to investigate the hypoglycemic, antilipidemic and antioxidant effects of valproic acid (VA) in alloxan-induced diabetic rats. VA (100, 300 and 600mg/kg p.o.) and insulin (17IU/kg s.c.) were administered once daily for 21 days. Fasting blood glucose level was determined at 7...

Full description

Saved in:
Bibliographic Details
Published in:European journal of pharmacology 2015-09, Vol.762, p.174-183
Main Authors: Akindele, Abidemi J., Otuguor, Edafe, Singh, Dhirendra, Ota, Duncan, Benebo, Adokiye S.
Format: Article
Language:English
Subjects:
Alloxan
Animals
Antilipidemic
Antioxidant
Antioxidants - pharmacology
Antioxidants - therapeutic use
Blood Glucose - metabolism
Body Weight - drug effects
Calcium - metabolism
Cytosol - drug effects
Cytosol - metabolism
Diabetes
Diabetes Mellitus, Experimental - blood
Diabetes Mellitus, Experimental - drug therapy
Diabetes Mellitus, Experimental - metabolism
Diabetes Mellitus, Experimental - pathology
Drinking - drug effects
Hydrogen Peroxide - metabolism
Hypoglycemic
Hypoglycemic Agents - pharmacology
Hypoglycemic Agents - therapeutic use
Hypolipidemic Agents - pharmacology
Hypolipidemic Agents - therapeutic use
Insulin-Secreting Cells - drug effects
Insulin-Secreting Cells - metabolism
Kidney - drug effects
Kidney - metabolism
Kidney - pathology
Lipids - blood
Liver - drug effects
Liver - metabolism
Liver - pathology
Male
Malondialdehyde - metabolism
Organ Size - drug effects
Rats
Rats, Wistar
Valproic acid
Valproic Acid - pharmacology
Valproic Acid - therapeutic use
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:This study was designed to investigate the hypoglycemic, antilipidemic and antioxidant effects of valproic acid (VA) in alloxan-induced diabetic rats. VA (100, 300 and 600mg/kg p.o.) and insulin (17IU/kg s.c.) were administered once daily for 21 days. Fasting blood glucose level was determined at 7 days interval. On day 21, blood samples were collected for assay of serum biochemical parameters (total protein, creatinine, urea, alanine transaminase (ALT), aspartate transaminase (AST), alkaline phosphatase (ALP), triglycerides (TG), total cholesterol (TC), high density lipoprotein (HDL), and low density lipoprotein (LDL)). Kidneys and livers were harvested for antioxidant indices and histopathological examination. In diabetic rats, VA produced a dose and day-dependent reduction in glucose level. Peak effect (52.79% reduction; P
ISSN:0014-2999
1879-0712
DOI:10.1016/j.ejphar.2015.05.044